Focus on Vastarel MR Reperfusion injury: reduction by Vastarel MR
نویسندگان
چکیده
Ischemia-reperfusion syndrome is defined as myocardial injury caused by the restoration of coronary flow. This phenomenon has a complex pathophysiology and results in a paradoxical reduction of the beneficial effect of myocardial reperfusion. Studies suggest that ischemia-reperfusion injury may account for up to 50% of the final size of a myocardial infarct. Vastarel MR (trimetazidine) is a pharmacological agent that shifts the preference for energy substrate away from fatty acid metabolism and towards glucose metabolism. Furthermore, it reduces intracellular acidosis, and protects against the toxicity induced by oxygen free radicals, which are key participants in ischemia-reperfusion injury. Accordingly, in animal studies a reduction in ischemia-reperfusion injury has been observed in association with the use of trimetazidine. These protective properties of trimetazidine over ischemia-reperfusion have also been suggested in clinical studies. Heart Metab. 2008;40:23–25.
منابع مشابه
Focus on Vastarel MR Effects of Vastarel MR on brain natriuretic peptide and cardiac troponin concentrations
Metabolic therapy represents an innovative approach to the treatment of coronary artery disease and heart failure. The metabolic modulator, trimetazidine (Vastarel MR), offers particular positive effects in reducing the cell loss and reorganization that characterize the process of left ventricle remodeling, and is useful in improving ischemic or failed cell metabolism. Correction of the metabol...
متن کاملFocus on Vastarel MR Beneficial long-term effects of Vastarel MR in patients with stable coronary artery disease developing left ventricular dysfunction
During the past two decades, the management of chronic coronary artery diseases has improved considerably, as a result of both pharmacotherapy and revascularization procedures. However, the course of chronic coronary artery disease, with an increase in the number of patients surviving after acute coronary syndrome, has led to an increase in the number of patients with ischemic left ventricular ...
متن کاملVastarel MR: from decades of clinical experience in stable angina to new perspectives
Trimetazidine has been known for years as being an effective, ‘‘patient-friendly’’, anti-anginal agent. Recent studies using the modified release formulation (Vastarel MR) have confirmed the efficacy of trimetazidine in stable ischemic heart disease and suggested that it can be beneficial in a number of
متن کاملFocus on Vastarel MR Clinical benefits of a metabolic approach in the treatment of ischemic heart disease: focus on Vastarel MR
Despite the recent decline in cardiovascular mortality, Ischemic Heart Disease (IHD) remains the leading single cause of death in the western world. Great hopes were provoked by the introduction of surgical and percutaneous myocardial revascularization techniques that promised to be a safe and effective alternative to control symptoms and to improve prognosis in these patients. Unfortunately, c...
متن کاملFocus on Vastarel MR Clinical overview of trimetazidine (Vastarel MR) in patients with heart failure
Myocardial energy metabolism may be normal in the early stages of heart failure but, as failure progresses, mitochondrial oxidative metabolism is reduced and glycolysis is increased, with downregulation of glucose oxidation. Reducing free fatty acid oxidation and a concomitant increase in glucose oxidation improve cardiac contraction and slow the progression of left ventricular failure. Trimeta...
متن کامل